Bone metabolism Product details

C-terminal Propeptide of Collagen Type-I

4818     CICP Control (Serum)       Set of 4 x 0.5 ml (4 levels)
Average: 40, 140, 245, 500 ng/ml

Serum, Heparin- and EDTA Plasma and cell culture

Avoid hemolysis of specimens. Keep samples refrigerated at 
2-8°C for storage of less than 5 days. For longer storage freeze specimens at -20°C or below.

Reference values from children are available.

Human, rabbit, cynomolgus macaque, porcine

The CICP Kit provides a quantitative method for the determination of collagen production. Collagen type-I is indicative for the collagen production in vivo. As the primary organic constituent of bone, type-I collagen levels have been linked to bone growth and formation. Elevated levels of CICP have been shown in diseases associated with high levels of bone turnover including Paget’s disease, hyperthyroidism, primary hyperparathyroidism and renal osteodystrophia. Frequently, the marker protein CICP has been used in growth deficient children and children with bone diseases. In addition, when metastases of cancer occur to sites in bone and/or liver, a greater proportion of individuals show elevated CICP levels in comparison to patients with other or without metastases.

CICP/PICP, ELISA, C-terminal propeptide of collagen type-I, Bone formation, Bone growth, Bone remodeling, Bone- and livermetastasis, Paget's disease, Hyperthyreosis, Bone marker, Renal osteodystrophia, primary Hyperparathyroidism